LAWRENCEVILLE, N.J. — September 2, 2025 — Leads & Copy — IMUNON, Inc. (NASDAQ: IMNN) announced today that a pre-recorded presentation from the Company will be available on demand as part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of IMUNON’s management team will also conduct in-person one-on-one meetings with investors September 8 – 10, 2025.
The presentation will be available beginning Friday, September 5, 2025, at 7:00 a.m. ET via pre-recorded webcast. The webcast will be available for 90 days at the provided link or under the News & Investors tab of the Imunon website.
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments. Their lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Media Contact:
Jenna Urban
CG Life
jurban@cglife.com
Investors Contact:
Peter Vozzo
ICR Healthcare
212-253-8881
peter.vozzo@icrhealthcare.com
Source: IMUNON
